As described in the ICH E5 guidelines, a bridging study is an additional study executed in a new geographical region or subpopulation to link or "build a bridge" from global clinical trial outcomes to the new region. The regulatory and scientific goals of a bridging study is to evaluate potential subpopulation differences while minimizing duplication of studies and meeting unmet medical needs expeditiously. Use of historical data (borrowing) from global studies is an attractive approach to meet these conflicting goals. Here, we propose a practical and relevant approach to guide the optimal borrowing rate (percent of subjects in earlier studies) and the number of subjects in the new regional bridging study.
INTRODUCTION
Modeling and simulation has been used widely in drug development for design and analysis of clinical trials, where data from multiple studies that have not followed a common protocol are combined. [1] [2] [3] An assumption of exchangeability underlies these analyses; this assumption is a judgement based on the domain knowledge of the context. Randomized clinical trials are considered the golden standard for evaluation of health care treatments, correctly sizing and powering a clinical trial is critical for scientific, regulatory, and business reasons. An underpowered trial provides limited scientific information and little support for drug registration. An overpowered trial, due to its unnecessarily large size, duration, and cost, squanders limited resources, which may be better spend elsewhere in the development program. To balance these conflicting priorities, we formalize a return on investment (ROI) viewpoint. We then apply Bayesian strategies to most efficiently borrow information from other prior studies, through application of the power prior method. 4 
The power prior
The power prior method allows for the incorporation of prior data and knowledge without assuming full exchangeability. 5 Let be a vector of parameters and D and D 0 be the data from a planned study and an historical study, respectively. The corresponding likelihood is denoted by L( |D) and L( |D 0 ). With a prior distribution 0 ( ), the corresponding posterior distribution of is given by ( |D, D 0 , a 0 ) ∝ L( |D)L( |D 0 ) a 0 0 ( ),
where 0 ≤ a 0 ≤ 1 is a scalar parameter that weights the historical data relative to the likelihood of the current study. 5 The term L( |D 0 ) a 0 0 ( ) on the right-hand side of the equation is called the power prior.
Motivation
We start with the viewpoints of Schoenfeld and Finkelstein 6 and Neelon et al, 7 in which the parameters in a pediatric study were estimated by borrowing a certain amount of information from its corresponding adult study for the same disease.
Here, we use a similar viewpoint to integrate information from a global drug program to inform the design and analysis of a regional bridging study, while controlling parameter uncertainty and avoiding overborrowing. With this context, consider̂G the estimate of the efficacy of interest in a global study, eg, the mean difference between a treatment group and the control group. Let √̂2 G ∕n G be the standard error, with n G the number of subjects observed in the global study. Similarly, let̂R and √̂2 R ∕n R be the efficacy of interest and standard error in a regional study, respectively. Assume that R and̂R can be a priori estimated by experts such as physicians and clinical statisticians, based on results from the global study, clinical experience, and literature review. Suppose that the prior p( R ) ∝ 1, once the number of subjects in the regional study n R and the borrowing rate a 0 is specified. The posterior distribution of R can then be obtained as follows.
We may view the posterior distribution as a function of power prior borrowing rate a 0 , regional study size n R . This enables us to assess the probability that R lies inside a specified acceptable range.
The rest of the paper is organized as follows. First, we confirm in Section 2 the essential roles of the borrowing rate a 0 in the power prior models from a hierarchical Bayesian point of view. Next, in Section 3, we show how the optimal borrowing rate can be determined in a practical manner. We then, in Section 4, retrospectively demonstrate application and robustness of the method using actual clinical trial data for dapagliflozin. This demonstration involves 24-week global and Japanese trials in type 2 diabetes, with primary outcome of change in HbA1c. In Section 5, we apply our approach to a prospective study design and confirm robustness of the study design and resulting optimal borrowing rate. Finally, we conclude in Section 6.
THE ESSENTIAL ROLE OF THE POWER PRIOR
As widely known, the power prior approach is similar to methods in hierarchical Bayesian models. 8 We further explore the role of a 0 in the design of bridging studies from the hierarchical Bayesian model perspective.
Hierarchical model and the power prior
We first demonstrate the relationship between power prior and hierarchical models. Let R , G be the means of parameters of interest in a regional study and a global study, respectively, and assume they are distributed around the universal mean with variance 2 . is further assumed to be distributed around 0 with variance 2 , as described in Figure 1 .
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Note sufficiently large sample size would allow application of the central limit theorem. The joint distribution R ,̂R,̂G is then
FIGURE 1
Distributions of means in a global study and regional study in hierarchical models From properties of multivariate normal distributions, the conditional distribution R |̂R,̂G under Equation (2) is
Note that the limit in corresponds to setting the prior of universal mean to noninformative, and as a result, the universal mean is absent from the equation. On the other hand, from Equation (1) and assuming p( R |̂R,̂R, n R ) and p( R |̂G,̂G, n G ) are normal,
Comparing Equations (3) and (4), the following relationship between a 0 and results. Note that a 0 = 0 (no borrowing) corresponds to = ∞ and a 0 = 1 (100% borrowing) corresponds to = 0.
As shown in Equation (5), the borrowing parameter a 0 has a direct relation to the interregional variability parameter , and knowing the extent of variability might be useful to access the borrowing parameter a 0 . In practice, global trials usually include multiple regions. Provided that such regional results are available, one can use it to get a referential estimates for the variability and to assess if the obtained a 0 is a realistic number; moreover, it can be involved in the analysis as a prior. It also should be noted that the model widely accepts any kind of parameters of interest as long as they are considered to be normally distributed. Once such an estimate for the parameter of interest is obtained, one can plug in the mean and variance into the power prior model.
Hierarchical models in a bridging study setting
Recall that 2 represents the variance of the prior distribution behind the parameters R and G . In other words, governs the intrinsic closeness of R and G to the universal mean , thus capturing the between-population variability. However,
FIGURE 2
Distributions of means in a global study and a regional study in hierarchical models in a more realistic setting when has a noninformative prior, represents the closeness between R and G . Using the geometry shown in Figure  2 , we show this is true in our specific setting.
It would be natural that, in general, a global study is closer than a regional study to the universal mean, because subjects in global studies contain multiple ethnicities. Moreover, one can consider the similarity between studies, eg, if the two studies are a Japan study and a China study, the subjects consist of only Asian people. Then one might apply different s for each study denoted by G , R and the similarity between studies (−1 ≤ ≤ 1).
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On the premise of Equation (6), the following expression can be obtained by applying the same calculation as Equation (3).
Note that the term
in Equation (7) plays the same role as the term 2 2 in Equation (3), so a 0 is a single calibrator. a 0 takes both variability from central mean and similarity between study populations into account, as long as is noninformative.
SELECTING THE BORROWING RATE
A number of methods 9,10,11 have been developed to choose the power prior parameter a 0 based on exchangeability and the similarity between outcomes. However, in our case, regional and ethnic variability is expected, and full exchangeability is not a realistic assumption. Characteristics of the study populations and study designs should also be identified, including physical characteristics of the patients, cultural differences in diet, regional variations in definition and diagnosis of the disease, known differences in pharmacokinetics, formulation and delivery differences for the drug, differences in dosing schedule and follow-up, and so on. If differences between the global and local studies are too substantial, limited or no borrowing is indicated.
Target ranges
In this section, we will show a practical way to determine an appropriate borrowing rate between regional and global studies. Note from Equation (1), we define
We consider several candidates for target ranges to meet both scientific and regulatory goals.
Examples of target ranges:
• upper and lower bounds of point estimates,
• upper bound on the standard error, and • lower or upper bounds of the 95% confidence interval of the efficacy outcome.
Consider the general case where there are h target ranges on R denoted by R 1 , … , R h and corresponding regions Q 1 , … , Q h on the (n R , a 0 ) plane. An optimal solution in terms of ROIn R and â 0 must lies inside the following acceptable design regionn
Moreover, one can prioritize each target range R i with a set of positive weights corresponding to each target ranges represented by w 1 , … , w h . For example, if the lower bound of the estimates (suppose it is denoted by R 1 ) is the first priority, one can set the corresponding weight w 1 = 1 and set the other weight to some numbers less than 1, eg, 0.8. We define a success probability S(n R , a 0 ), which take the priority take into account as follows.
ROI and cost structure
From the perspective of ROI, S(n R , a 0 ) can be considered to be proportional to return. A typical trial cost structure, on the other hand, includes both fixed cost (F) and variable unit cost (u). The driving component of variable cost is the number of subjects n R , since other variable costs such as number of doctors, sites, and recruitment time tend to scale with the total number of subjects. The total cost C, fixed plus variable, can be expressive as
where f ∶= F∕u. Then ROI can be expressive as a function of n R and a 0 .
When the relative fixed cost f is small, the portion of f in the denominator becomes small, then the number of subjects in regional study n R has much more impact on ROI than when it is small, and vice versa. And optimal solutionn R and â 0 can be defined as follows.n
A RETROSPECTIVE EXAMPLE
We first consider a fully retrospective analysis of a global study followed by a fully powered regional bridging study. This allows us to demonstrate operating characteristics of our approach in a case when the large regional study provides high confidence information of the global-regional differences. Consider trial data from initial pharmacotherapy of type 2 diabetes with the sodium-glucose cotransporter-2 inhibitor dapagliflozin for global 12 and Japan 13 studies. These studies are 24-week, randomized, double-blind, and placebo-controlled studies. The primary outcome of both studies is mean difference between treatment group and placebo group in adjusted mean change from baseline (95% CI) for HbA1c. Study results for 10 mg are summarized in Table 1 . Note, in this case, that regional differences are suggested in both effect size and variability. For study design, consider the following target ranges. Let̂be the point estimates for R and̂be its standard error. The boundary of Q 1 and Q 2 is then
We evaluate S(n R , a 0 )
where er is the error function: er (x) = 2 √ ∫
x 0 e −t 2 dt. For example, suppose Bias l = 0.3, Bias u = 0.5, LB 95 = 0.2 and w 1 = w 2 = 1, which means one expects that the point estimate should be inside the range [0.3, 0.5] and lower bound of 95% confidence interval should be more than 0.2 to meet regulatory requirements. Considering Equations (9) and (10), We draw the above boundaries in the n R , a 0 plane as shown in Figure 3 . The area unshadowed is the acceptable region. The area Q 1 (between the two solid lines) indicates that the bias resulting from borrowing is too strong, so the borrowing rate based on n R is too high. On the other hand, the area Q 2 (between two dashed lines) indicates that the effective sample size n R + a 0 (̂2 R ∕̂2 G ) n G is insufficient to control the posterior standard error. If the goal is to reduce the number of Japanese subjects as much as possible without consideration of risk, we would choose (a 0 = 0.4, n R = 17). Considering Equation (8), we can balance reduction of trial size against other aspects of ROI. To further illustrate, we consider a cost structure typical of this indication in Japan and choose f R = f G = 83. Solving equations numerically with a grid search results in Figure 4 .The optimal borrowing rate and regional study size, (a 0 , n R ), are (0.31, 50). Note the decrease in study size of almost half for 10 mg. The ROI is shown in Table 2 .
A PROSPECTIVE EXAMPLE
The example in Table 1 benefits from availability of trial results from fully powered studies for globally and regionally. This provides a retrospective validation of the potential benefits of the ROI optimization technique, since both global and regional parameters are well estimated. In application of ROI optimization for designing future bridging studies, this is not the case. Instead, we start with a plausible design point for the regional bridging study, optimize the study based on ROI, and then assess the robustness of the operating characteristics of the design around this plausible design point. As an illustration base on our example in Table 1 , consider the regional design point * R , * R with regional mean efficacy at 80% of global results and similar population variance, * R = 0.4 and * R =̂G
The resulting geometry is shown in the left side of Figure 5 , with contours showing the level sets of the ROI and the two constraints illustrated. The optimal design point inside the acceptable region is a * 0 = 0.31, n * R = 63 (black marker), as shown in Figure 5 . This point is at the boundary of our "insufficient confidence" constraint, so the lower bound of the 95% confidence interval is equal to 0.2. Reducing either the borrowing rate or the study size would result in insufficient confidence in the final bridging study data analysis, assuming of course that the specified design point is correct.
Robustness of the design
Once a design point is selected, it should be checked how robust the study point is, because the actual data can be violating main assumptions made. We now consider robustness of the design by considering performance if regional truth varies significantly from our assumed design point of * R = 0.4 and * R = 1.23. Fix a 0 = 0.31, n R = 63 and consider true (but unknown) regional R , R in the context of performance constraints Q 1 and Q 2 . With design a 0 = 0.31, n R = 63, and regional performance R , R specified, we can identify whether the performance constraints Q 1 and Q 2 are met. This is indicated by shading, as shown in the right side of Figure 5 . If we use design a 0 = 0.31, n R = 63 and the true performance R , R is in the shaded region, the study will likely fail due to failing regulatory targets or conclusion of overborrowing. A location of the design point * R and * R in the interior of the unshaded region indicates some level of robustness margin for the proposed regional design a 0 = 0.31, n R = 63, since the proposed design would still meet quality constraints Q 1 and Q 2 even if the actual (but unknown) regional effect size and variability R , R differ somewhat from the assumed design point. As seen in the right side of Figure 5 , the design choice a 0 = 0.31, n R = 63 has limited robustness. Slightly smaller true (but unknown) regional effect size or larger regional population variability R , R may lead to insufficient confidence in the bridging study result. The lower limit of the 95% confidence interval for the effect size would not reach regulatory requirements, and the study would fail. Designs close to the constraint boundaries are at higher risk of failure due to oversharing or overly wide confidence intervals. We see from the left side of Figure 5 that we can increase robustness by picking a design from an almost-minimum contour of ROI, which is in the interior of the acceptable region. Robustness to uncertainty in the regional design point can then be verified as in the right side of Figure 5 .
CONCLUSIONS
We explored a novel and practical way of designing bridging studies and optimal borrowing rate a 0 and study size by considering both constraints on performance and optimal ROI. This allows us to protect against overborrowing while controlling the precision of resulting regional efficacy estimates. Using an expert-provided design point, we explored methods to establish the robustness of the operating characteristics of the resulting Bayesian bridging study. Although the method would be helpful to be used for study design consideration, the method does not take uncertainty of the borrowing parameter into account at all, which corresponds to the case where the borrowing parameters is fixed between study variation. It might not be adequate to apply only for analysis. On the other hand, if it is applied throughout the study, ie, from design phase to analysis phase, it should have less problems.
